A retrospective study to compare short and long-term efficacy, safety, and drug survival of anti TNF-alpha, anti-IL-17, and anti-IL-23 inhibitors in patients with Psoriasis
Latest Information Update: 26 Jul 2022
At a glance
- Drugs Brodalumab (Primary) ; Guselkumab (Primary) ; Ixekizumab (Primary) ; Secukinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
Most Recent Events
- 26 Jul 2022 New trial record
- 01 Jun 2022 Results published in the Journal of Dermatological Treatment